APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa
Objective: Evaluate if any differences exist in the efficacy of APL-130277 doses to turn a patient with Parkinson's disease (PD) from OFF to fully ON…Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson’s disease
Objective: Determine the pharmacokinetic/pharmacodynamic effects of APL-130277 on OFF episodes in patients with Parkinson's disease (PD). Background: APL-130277 is a sublingual film being studied in…Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)
Objective: Determine the minimum MDS-UPDRS Part III improvement needed to convert a patient from the morning OFF state to a full ON with APL-130277. Background:…PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program
Objective: To determine if outcomes following a PT program are improved if PT sessions are conducted while PD patients are in an on motor state…Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece
Objective: To evaluate the long-term efficacy of subcutaneous apomorphine (APO) injection and APO infusion in controlling motor fluctuations and dyskinesias and the impact on quality…Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital
Objective: To evaluate a cohort of people with Parkinson's disease (PD) who were initiated on subcutaneous apomorphine injections or continuous subcutaneous apomorphine infusions (CSAI) on…Therapy escalation in Parkinson’s disease – The TEMP trial, a regional survey
Objective: To assess socio-demographic and disease specific data in patients with Parkinson's disease (PD) before and one year after therapy escalation with subcutaneous apomorphine (APO),…ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump
Objective: To characterize the local safety and PK of a novel apomorphine formulation, ND0701, in comparison to a commercially available apomorphine–HCl solution. Background: Apomorphine is…Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany
Objective: To evaluate the duration of treatment (DOT) and safety of apomorphine continuous subcutaneous infusion (CSI) in patients with advanced PD inscribed in a managed…Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature
Objective: To examine the histology of subcutaneous nodules after continuous subcutaneous apomorphine infusion (CSAI). Background: CSAI has been used successfully in advanced Parkinson's disease (PD).…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.